Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).
Background: The three interferon beta preparations approved for treatment of relapsing-remitting multiple sclerosis (MS) differ in dose and frequency of administration. Interferon beta-1a 30 microg is administered once a week, interferon beta-1a 22 microg or 44 microg is given three times a week, an...
| Publicado en: | Lancet Vol. 359; no. 9316; pp. 1453 - 1461 |
|---|---|
| Autores principales: | , , , , , , , |
| Formato: | clinical trial research randomized controlled trial Journal Article |
| Publicado: |
Lancet
4/27/2002
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=6556891&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 6556891 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 01406736 LAN jtl: Lancet issn: 01406736 maglogo: N pubinfo: dt: 4/27/2002 vid: 359 iid: 9316 pid: 1297 pub: Lancet place: Philadelphia, Pennsylvania artinfo: ui: 6556891 6556891 NLM11988242 6556891 10.1016/S0140-6736(02)08430-1 NLM11988242 6556891 ppf: 1453 ppct: 8 formats: fmt: – @attributes: type: T – @attributes: type: C – @attributes: type: P tig: atl: Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). aug: au: Durelli, Luca Verdun, Elisabetta Barbero, Pierangelo Bergui, Mauro Versino, Elisabetta Ghezzi, Angelo Montanari, Enrico Zaffaroni, Mauro sug: subj: Interferons Therapeutic Use Biological Response Modifiers Therapeutic Use Multiple Sclerosis Drug Therapy Interferons Adverse Effects Prospective Studies Time Factors Drug Administration Schedule Male Biological Response Modifiers Adverse Effects Human Liver Recurrence Liver Drug Effects Multiple Sclerosis Pathology Fatigue Chemically Induced Treatment Outcomes Adult Disease Progression Fever Chemically Induced Female Depression Chemically Induced Clinical Trials Validation Studies Comparative Studies Evaluation Research Multicenter Studies Randomized Controlled Trials Scales Adult: 19-44 years Male Female ab: Background: The three interferon beta preparations approved for treatment of relapsing-remitting multiple sclerosis (MS) differ in dose and frequency of administration. Interferon beta-1a 30 microg is administered once a week, interferon beta-1a 22 microg or 44 microg is given three times a week, and interferon beta-1b 250 microg is administered on alternate days. No clinical study directly comparing the different regimens has been published. The INCOMIN study was designed to compare the clinical and magnetic resonance imaging (MRI) benefits of on-alternate-day interferon beta-1b 250 microg with once-weekly interferon beta-1a 30 microg.Methods: INCOMIN was a 2-year, prospective, randomised, multicentre study. 188 patients with relapsing-remitting MS were assigned to interferon beta-1b (n=96) or interferon beta-1a (n=92). Primary outcome measures were the proportion of patients free from relapses and that of patients free from new proton density/T2 lesions at MRI assessment. Several secondary outcome measures were also assessed. Analysis was by intention to treat.Findings: Over 2 years, 49 (51%) individuals administered interferon beta-1b remained relapse-free compared with 33 (36%) given interferon beta-1a relative risk of relapse 0.76; 95% CI 0.59-0.9; p=0.03); and 42 (55%) compared with 19 (26%), respectively, remained free from new T2 lesions at MRI (relative risk of new T2 lesion 0.6; 0.45-0.8; p<0.0003). In both groups, the differences between the two treatments increased during the second year. There were also significant differences in favour of interferon beta-1b in most of the secondary outcome measures, including delay of confirmed disease progression.Interpretation: High-dose interferon beta-1b administered every other day is more effective than interferon beta-1a given once a week. pubtype: Academic Journal doctype: clinical trial research randomized controlled trial Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|